No arguments for extra risk from ibuprofen in SARS-COV2 infection.

Moore, Nicholas

Moore, Nicholas.

Moore N; Bordeaux PharmacoEpi, Inserm CIC1401, université de Bordeaux, 146, rue Léao Saignat, 33076 Bordeaux cedex, France. Electronic address: nicholas.moore@u-bordeaux.fr.

Therapie ; 75(5): 513-514, 2020.

Article in French | MEDLINE | ID: covidwho-639768

Subject(s)

COVID-19 Drug Treatment; Ibuprofen/adverse effects; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use; COVID-19/epidemiology; COVID-19/pathology; Chronic Disease; Confounding Factors, Epidemiologic; Disease Progression; Fever/complications; Fever/drug therapy; Fever/epidemiology; France/epidemiology; Humans; Ibuprofen/administration & dosage; Pain/complications; Pain/drug therapy; Pain/epidemiology; Pandemics; Practice Guidelines as Topic/standards; Rheumatic Diseases/drug therapy; Rheumatic Diseases/epidemiology; Risk Factors; SARS-CoV-2/physiology; Severity of Illness Index

Keywords

COVID-19; Ibuprofen; SARS-CoV2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ibuprofen / COVID-19 Drug Treatment Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Humans Country/Region as subject: Europa Language: French Journal: Therapie Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google